Janssen: New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM? (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients

Related Keywords

Janssen Cilag Gm ,Alexandra Nisipeanu ,Jennifer Mcintyre ,Prinzj Ponesimod ,Janssen Cilag International ,None Of The Janssen Pharmaceutical Companies ,European Commission ,National Multiple Sclerosis Society ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Actelion Pharmaceuticals Ltd ,Exchange Commission ,Janssen Global Services ,Companies Of Johnson ,Idorsia Pharmaceuticals Ltd ,Johnson ,European Committee ,Treatment Research ,Multiple Sclerosis ,About Multiple Sclerosis ,Pharmaceutical Companies ,Cardiovascular Metabolism ,Infectious Diseases Vaccines ,Janssen Cilag ,Concerning Forward Looking Statements ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Scler Relat ,Adv Chronic ,Once Daily ,Moral Therapy ,Relapsing Forms ,Active Disease Defined ,Janssen ,Subgroup ,Analysis ,Hase ,Optimum ,Study ,Emonstrates ,Benefits ,Onvorytm ,Onesimod ,Dover ,Teriflunomide ,Early ,Disease ,Multiple ,Clerosis ,